Is it time for a new attitude to “simultaneous” bilateral cataract surgery?

Guy T Smith, Christopher S C Liu

Almost every discussion on simultaneous bilateral cataract surgery (SBCS) for senescent cataracts begins with a comment on its controversial nature. The question is can the benefits of bilateral surgery justify the risk of simultaneous bilateral complications, in particular endophthalmitis? Operating on the second eye immediately after the first is an option that does have potential advantages. These can be separated into the clinical benefits to the patient and economic benefits to the patient, hospital, and society. It is the benefits and risks to the patient that are our primary duty as clinicians, and they will be the focus of this discussion. In this perspective we present an approach to “simultaneous” bilateral cataract extraction, and examine the risk of unilateral or bilateral complications following cataract extraction in light of the perceived benefits as they apply at the beginning of the 21st century. The aim of the perspective is to remove the stigma from “simultaneous” bilateral cataract surgery, so that suitable patients may be offered this method of delivery of treatment.

Our approach to simultaneous bilateral cataract surgery

We begin by assuming that all patients are suitable for simultaneous bilateral cataract surgery (SBCS), unless they have a specific contraindication that increases the risk of complications (Table 1). These are broadly divided into conditions that increase the risk of endophthalmitis, lenticular abnormalities, extremes of axial length, and keratometry that may make the biometry unreliable and conditions that may predispose to postoperative corneal oedema or decompensation, raised intraocular pressure, ocular inflammation, and retinal detachment. An informal survey of patients seen at our cataract clinic would suggest that up to one third of patients would be excluded by these criteria. Currently we do not carry out extensive preoperative systemic investigations on our patients and, therefore, there does remain an element of risk that there may be an undiagnosed condition such as leukaemia.

When visually significant bilateral senescent cataracts are diagnosed in the absence of exclusion criteria, the perceived risks and benefits of SBCS are discussed with the patients (Table 2). The patients’ names are put on the waiting list for SBCS or unilateral cataract surgery, as they prefer. At preassessment, patients undergo a further full ocular examination and biometry. The perceived risks and benefits of SBCS are discussed again before seeking consent. If an exclusion criterion is present unilateral rather than SBCS is offered.

On the day of surgery the eyes are briefly examined again preoperatively to ensure that no contraindications to SBCS are present. If an exclusion criterion is present unilateral surgery is performed.

To the patient

- One general anaesthetic, where required, for surgery
- Improved visual function
- One step visual rehabilitation
- No anisometria between operations
- One pair of new glasses
- Fewer hospital visits

To the hospital

- Only one preassessment visit
- Only one admission for surgery
- More efficient use of theatre time
- More efficient use of clinic

To society

- Shorter waiting lists for surgery and clinics
- Accompanying friends and relatives take less time off work
- Less demand on hospital transport services

<table>
<thead>
<tr>
<th>Benefits</th>
<th>Risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>First eye intraoperative complications result in unilateral surgery</td>
<td>Vitreous exposure</td>
</tr>
<tr>
<td>Endophthalmitis*</td>
<td>Suprachoroidal haemorrhage*</td>
</tr>
<tr>
<td>Hyphaema</td>
<td>Raised IOP</td>
</tr>
<tr>
<td>Iris prolapse</td>
<td>Cystoid macular oedema</td>
</tr>
<tr>
<td>Refractive surprise</td>
<td>Epithelial ingrowth*</td>
</tr>
<tr>
<td>Corneal decompensation</td>
<td>Fungal endophthalmitis*</td>
</tr>
</tbody>
</table>

Table 1 Exclusion criteria for immediately sequential cataract surgery (ISCS)

<table>
<thead>
<tr>
<th>Exclusion criteria</th>
<th>ISCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased risk of infection</td>
<td>Active adnexal and ocular surface infection (including untreated blepharitis, mucocoele)</td>
</tr>
<tr>
<td></td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td>Immunosuppression and immunodeficiency (including systemic steroids)</td>
</tr>
<tr>
<td></td>
<td>Leukaemia/lymphoma</td>
</tr>
<tr>
<td></td>
<td>Iodine allergy</td>
</tr>
<tr>
<td>Increased risk of corneal decompensation</td>
<td>Endothelial dystrophy</td>
</tr>
<tr>
<td></td>
<td>Glaucoma</td>
</tr>
<tr>
<td>Increased risk of inaccurate biometry</td>
<td>High myopia or AL &gt;26 mm</td>
</tr>
<tr>
<td></td>
<td>High hyperopia or AL &lt;21 mm</td>
</tr>
<tr>
<td></td>
<td>AL difference between the eyes &gt;1 mm (unless supported by corresponding anisometria)</td>
</tr>
<tr>
<td></td>
<td>Previous refractive surgery</td>
</tr>
<tr>
<td>Lenticular abnormalities</td>
<td>History of ocular trauma</td>
</tr>
<tr>
<td></td>
<td>Lens subluxation</td>
</tr>
<tr>
<td></td>
<td>Phacodonesis</td>
</tr>
<tr>
<td></td>
<td>Pseudoexfoliation</td>
</tr>
<tr>
<td>Increased risk of high IOP</td>
<td>Glaucoma</td>
</tr>
<tr>
<td></td>
<td>Trabeculectomy</td>
</tr>
<tr>
<td></td>
<td>Previous iritis</td>
</tr>
<tr>
<td>Unocular cataract</td>
<td></td>
</tr>
</tbody>
</table>
have developed. The first eye to be operated on is marked as such and the pupils are dilated with phenylephrine 2.5% eye drops and cyclopentolate 1% eye drops four times an hour before surgery. Topical antibiotics are not used preoperatively. Diclofenac 0.1% eye drops four times an hour before surgery are instilled to stabilise the blood-aqueous barrier and inhibit intraoperative miosis.

The surgical team is well established and familiar with the operative technique. The surgery is usually carried out under general anaesthesia but may very occasionally be done under sub-Tenon’s or topical anaesthesia. We prefer not to use peribulbar anaesthesia to avoid the small risk of bilateral ocular perforation, and poor vision in both eyes in the immediate postoperative period. The masked surgeon instils aqueous povidone iodine 5% into the conjunctival fornices of both eyes, followed by cleaning of the lids, cheek, nose, and brows working concentrically away from the eyes. The skin is dried before the drape is placed with the eye held open and lashes fully everted. A horizontal cut in the plastic material divides the plastic to be folded under the upper and lower lids, so the speculum traps the lashes and excludes the meibomian gland orifices from the surgical field. The drape is also pressed against the skin on the side of the nose to exclude communication with the anterior nares. The face is turned slightly to prevent pooling of irrigating fluid on the ocular surface.

Usually, a superiorly sited astigmatically neutral scleral tunnel is fashioned. A “divide and conquer” technique is usually used for phacoemulsification and is usually a 5.5 mm diameter optic one piece poly(methylmethacrylate) (PMMA) lens. The viscoelastic is removed, the wound checked for integrity and sutured if necessary with 10/0 Vicryl. The conjunctival flap is replaced over the scleral wound, subconjunctival cefuroxime is injected, and the eye is padded. If there are any complications such as posterior capsular breach, zonular dehiscence, excessive operating time, or phacoemulsification energy, surgery to the second eye is postponed. For this reason the term “simultaneous” bilateral cataract surgery is a misnomer for this type of surgery. Neither the surgeon nor the patient is irrevocably committed to having the second eye operated on unless everything has gone perfectly with the first eye. For this reason we prefer the term immediately sequential cataract surgery (ISCS).

Before the second eye is operated on, the surgeon and assistant rescrub. Alternatively, another surgeon and assistant scrub as the first eye operation comes to an end. The second eye is cleaned again with povidone iodine 5%. The same surgical technique is used for the second eye. When both eyes have been operated on, a clear Cartella shield is applied to each eye, and the patients are taken back to the ward following recovery. Later an ophthalmologist from the operating team examines the patient for any complications before discharge. If surgery to the second eye has been cancelled, it is explained to the patient that the second eye will be operated on at a later date when the first eye is fully recovered. Patients are discharged on a regimen of steroid eye drops four times daily and antibiotic eye drops four times daily until reviewed in the follow up clinic. They are informed that if they experience problems with either eye—for example, increased redness, pain, or decreased vision, they should telephone or reattend immediately. This protocol has been successful with our unilateral phacoemulsifications.

Steps are taken to avoid epidemic endophthalmitis, the instruments are taken from a “phaco pack” held back from the previous week’s batch, the sterility of that batch having been “proved” by the previous week’s surgery. Intraocular substances such as adrenaline, antibiotics, or anaesthetic agents are not routinely used. Viscoelastic materials and balanced salt solutions made by different manufacturers, or from different batches if from the same manufacturer, are used for each of the two eyes.

**Why take the risk of performing immediately sequential bilateral phacoemulsification?**

The results from our unilateral surgery are stable and successful. Operating on the second eye immediately after the first is an option that has potential advantages.

**ADVANTAGES TO THE PATIENT**

**Improved visual function**

The expectations of patients are increasing all the time. It is no longer enough to remove the lens opacity, we must also try to optimise the patients’ visual function. Visual perception is a highly complex multidimensional function, involving vernier acuity, colour perception, contrast sensitivity, and a host of other factors. The Snellen acuity is a measure of the patient’s ability to resolve high contrast optotypes in minutes of arc, it only provides limited information about the patient’s visual function, and none on the day to day effects of cataracts. Despite being firmly established, it should not be the sole criterion by which visual impairment caused by cataract and outcome of surgery are measured. Rather, “cataract surgery is indicated when a cataract causes functional disability considered by the patient to be sufficiently problematic to warrant undertaking the risks of cataract surgery, regardless of the VA of that patient.” A “gold standard” for functional impairment related to vision does not exist. Several subjective measures of patients’ visual function have been established. The VF 14 shows moderate correlation with the visual acuity (VA) in the better eye, and the relation between the preoperative measured visual acuity and the Activities of Daily Vision Score (ADVS) is also stronger for the better eye. This suggests that the ability to perform many vision dependent activities is determined more by the acuity of the better eye than the acuity of the worst or the binocular vision. Despite this, a number of studies have shown that operating on the second eye gives a significant improvement in visual function and quality of life. In 1993 Javitt and colleagues addressed the relative impact of surgery for the first, second, or both eyes simultaneously. The results from our unilateral surgery are stable and successful.

**Sequential bilateral phacoemulsification?**

For this reason we prefer the term immediately sequential cataract surgery (ISCS).

**Feeder visits to the hospital**

Many patients have limited mobility in the preoperative and perioperative period which makes getting to hospital difficult. This often means that a relative or friend has to
Is it time for a new attitude to “simultaneous” bilateral cataract surgery?

In December 1997 the cataract surgical problem in the UK was as follows. The number of patients on the waiting list was oversubscribed. The reduced number of visits not only saves the patients’ time, but also their friends’ and relatives’ time, and risks, using published data following a Medline search. The complications can be categorised as intraoperative, early postoperative, and late postoperative, and subdivided into catastrophic and non-catastrophic. A catastrophic complication is one in which there is a reasonable likelihood of permanent visual loss in the affected eye.

INTRAOPERATIVE COMPLICATIONS
These are minimised with ISCS by not proceeding to the second eye if there are intraoperative complications with the first eye.

NON-CATASTROPHIC COMPLICATIONS
Vitreous exposure is the most important intraoperative complication, it is associated with a 5.3-fold (1.8 times to 16 times, p=0.002) risk of endophthalmitis and also increases the risk of postoperative cystoid macular oedema. In a modern series of 319 cases of immediately sequential extracapsular cataract extraction (ECCE) Beatty and colleagues reported posterior capsule rupture in five eyes (0.8%) and vitreous loss in two eyes (0.3%). No patient had both eyes affected. Although there was one case of endophthalmitis (0.16%) it was not stated if the posterior capsule had been breached.1 Ramsay and colleagues reported a posterior capsule rupture rate of 5% with vitreous loss in 3%, there was one case of bilateral vitreous loss during 453 cases of immediately sequential ECCE.1 Diaper and colleagues reported three cases of posterior capsule rupture (2.4%), one requiring vitrectomy (1.2%), and one case of zonular dehiscence (1.2%) during 41 cases of ISCS; none was bilateral and there were no cases of endophthalmitis.2 Pearce stated that during 129 cases of ISCS there were two holes in the posterior capsule (0.8%) but no vitreous loss or endophthalmitis.17 Potamitis and colleagues reported no complications during 66 cases of ISCS.19 These figures compare favourably with the national rate of posterior capsular rupture and vitreous loss of 4.4% seen during unilateral cataract extraction surgery,14 and previously published rates of posterior capsular rupture and vitreous loss during phacoemulsification are 1.4–5.2% and 0.7–2.3% respectively,16 20 and during ECCE are 0–8%.21 22 and 0.09–3.3%,23 24 respectively.

CATASTROPHIC COMPLICATIONS
Suprachoroidal haemorrhage rates vary depending on the method used for cataract extraction, and the criteria used for diagnosis. We have been able to find eight reports of bilateral suprachoroidal haemorrhage associated with cataract surgery, (0.004%).24–28 In 15 eyes it occurred after intracapsular cataract extraction (ICCE), two of which were immediately sequential ICCE and one after ECCE. The outcome was the loss of both eyes in five cases, bilateral no perception of light (NPL) in one case, and 6/9 or better in two cases. In Payne’s series of four, three had glaucoma, the interval between surgery varied from 4 days to 4 years, one patient’s suprachoroidal haemorrhages occurred 12 hours postoperatively, and the ECCE achieved 6/9 acuity after 1 year of follow up.28 One large series estimated a rate of 0.013% following phacoemulsification and 0.12% following ECCE where cases converted to ICCE are excluded (p = 0.0003). There were three cases occurring during phacoemulsification and all were limited, two of these were associated with posterior capsule rupture and took 8 and 12 weeks to resolve and achieved 0.5 and 0.8, respectively. The other case took 6 weeks to resolve and achieved 0.3 acuity.29 The outcomes from another large series where phacoemulsification and ECCE were not divided were: 41% achieved 6/6–6/30, 6% achieved 6/60–6/120, 3% achieved 6/120 to hand movements (HM), 29% were perception of light (PL), and 15% were NPL.26 A number of risk factors have been identified which increase the risk of occurrence, glaucoma 5.0 times (2.2–12.6, p <0.0001), axial length >24 mm 4.7 times (2.0–
11.3, p <0.0001), intraoperative pulse rate more than 85
21.8 times (6.4–73.9, p <0.0001). Hypertension and
diabetes mellitus were not significant risk factors. There
were no cases of suprachoroidal haemorrhage associated
with simultaneous bilateral phacoemulsification or
ECCE.1–3 17 19 31 32

Patients with glaucoma and extremes of
axial length are excluded from ISCS (Table 1).

EARLY POSTOPERATIVE COMPLICATIONS

Catastrophic complications

Endophthalmitis is widely regarded as a devastating compli-
cation of intraocular surgery. This has generated a huge
amount of research on endophthalmitis. However,
because of its relatively low incidence it is hard to clearly
identify all the factors in its development. It has been
established by DNA analysis techniques that the micro-
organisms causing endophthalmitis are commonly the
patients’ own commensal bacterial flora. The pooled data
from anterior chamber contamination studies do not seem
to relate to the endophthalmitis rate, despite culturing
an organism from 20–29% of anterior chambers, there were
no clinical cases of endophthalmitis in 510 cases studied.
Preoperative antibiotics were not used in any of these
studies, which suggests that an otherwise healthy eye
can handle a small inoculum of bacteria (all of these
studies excluded patients with ocular surface diseases,
who might be expected to have different bacterial profiles
and be at higher risk of endophthalmitis). Similarly, although
there was agreement that prophylactic antibiotics can be
effective in reducing, but not eliminating, the risk of
endophthalmitis, the optimal dosage, frequency, timing,
and type of antibiotic have not been determined. There
were two cases of unilateral endophthalmitis after immedi-
ately sequential ECCE (0.16% and 0.19% respectively). Bolger
reported that after 350 cases of simultaneous bilat-
eral cataract extraction there were two cases of endoph-
thalmitis in different patients, a rate of 0.29%, consistent
with the rate in his unilateral surgery and other surgeons’
published data. Of the 2859 mixed immediately sequential
ECCE and phacoemulsification cases, there were four
cases of endophthalmitis, none bilateral, a rate of
0.14%. This compares well with the national endophthalmitis rate of 0.1%14; our endophthalmitis rate
following unilateral cataract extraction (0.12%), and
figures published for endophthalmitis after uncomplicated
ECCE (0.18%), complicated ECCE (1.10%), uncomplic-
ated phacoemulsification (0.18%), and complicated
phacoemulsification (2.42%). There has been one
report of bilateral endophthalmitis following cataract
surgery separated by 1 year. The presentation and
outcome of endophthalmitis is strongly linked to the class
of organism isolated. The acute form, has a fulminating pre-
sentation 2–4 days postoperatively. It is most frequently
caued by virulent organisms such as Staphylococcus aureus
(80–90%), streptococci (9–22%), and Gram negative
organisms (6–22%), and has a poor visual prognosis (6/12
or better in 10–20%). The delayed form occurs 5–7 days
postoperatively, and is usually due to organisms of low
virulence, such as the coagulase negative staphylococci and
Propionibacterium spp (55–100%), it is less severe and
tends to be associated with a better outcome (6/12 or bet-
er in 46–100%). The size of the inoculum and specific host factors may influence the course of an
individual case follows. When considering ISCS, conditions
which might increase the bacterial load of the lids or con-
junctiva, or which might impair the eye’s natural defences
are exclusion criteria (Table 1). When performing ISCS
povidone iodine and postoperative subconjunctival antibi-
otics are always used to reduce bacterial viability and
patients with an increased risk of infection are excluded
(Table 1) to minimise the chance of endophthalmitis. Second eye surgery is delayed if there is vitreous exposure,
and a lens design with a proved “track record” is used. Lenses with polypropylene haptics were found to have a
higher endophthalmitis rate than one piece PMMA lenses,
0.19% and 0.04% respectively. Steps taken to minimise
the risk of epidemic endophthalmitis are minimal use of
intracameral drugs, using viscoelastics, balanced saline
solution, lenses from different batches, and instruments
already proved by previous surgery. Waiting 48 hours is
probably not long enough to be sure that a virulent organ-
ism is not going to cause simultaneous bilateral endoph-
thalmitis. In one study only 86% of cases of endoph-
thalmitis had presented by 34 days.

NON-CATASTROPHIC COMPLICATIONS

Iris prolapse was seen bilaterally after immediately sequen-
tial ECCE in one patient (0.18%), whose visual acuity at
the last follow up visit was 6/9.1 Unilateral iris prolapse
occurred in 0.6%. There are no reports following
immediately sequential phacoemulsification. Both eyes
were affected with 0.98% of unilateral ECCE and 0.2% of
unilateral phacoemulsifications. In these cases of single
eye surgery the scleral tunnel had been enlarged for a
7 mm lens but not sutured, all occurred on the first postop-
erative day, two resolved spontaneously, and one required
repositioning. There were no cases following scleral tunnel
and 5.5 mm lens insertion.

Hyphaema was seen in 0.8% of cases following immedi-
ately sequential ECCE1 and in 0–1.2% following immedi-
ately sequential phacoemulsification. Both eyes were
affected in 0.3–1.5% and the final visual acuity was 6/12 or
better. The national rate for unilateral surgery was 1.3% on
the first postoperative day and had resolved in all cases by
3 months.

Transient intraocular pressure (IOP) elevation was seen in
3.0% after immediately sequential ECCE, two cases were
bilateral (0.6%) and all achieved 6/12 acuity or better.1
Transient IOP elevation occurred in 3.7% after immedi-
ately sequential phacoemulsification, but resolved by the
second postoperative day. The national rate in 1993 for
unilateral surgery was 5.3% on the first postoperative
day and 2.3% by 3 months. Removing the viscoelastic from
the anterior chamber at the end of surgery and the wide
variety of agents for controlling intraocular pressure will
help to reduce the frequency of this complication. We
exclude patients from ISCS who are susceptible to
increased postoperative anterior chamber inflammation
with subsequent IOP rise, and glaucoma patients who may
not tolerate a transient elevation in IOP.

Retinal detachment/tear was seen in one eye (0.2%) after
immediately sequential ECCE and achieved a final acuity of
6/12. A second retinal detachment occurred as a complica-
tion of pars plana vitrectomy, 86–91% of retinal detachments
were reported after ISCS. In one study only 86% of cases of
endophthalmitis had presented by 34 days.47

Weber-Smith, Liu 1492
www.bjophthalmol.com
Late postoperative complications

Catastrophic complications

Fungal endophthalmitis is rare and usually has a delayed presentation. It comprises 0–16.7% of cases in the published series on endophthalmitis. We have been able to find reports of 33 cases of fungal endophthalmitis following ECCE or phacoemulsification from North America and Europe published during the 1990s. There were no cases from the UK published during the 1990s. The median onset was at 21 days (range 3–77 days), and the visual outcome varied, five were 6/7.5 or better, three were 6/30, four were 6/60, one was HM, one was NPL, and five were enucleated or eviscerated. We have found only one report of simultaneous bilateral fungal endophthalmitis presenting after sequential phacoemulsification through a scleral tunnel, the surgeries were 3 weeks apart. The visual outcome was 6/120 in one eye with an epiretinal membrane and 6/7.5 in the other eye. Epidemiology of fungal endophthalmitis can be caused by contamination of batches of solutions and ventilation systems. There is a report of fungal endophthalmitis occurring over a 49 day period. The visual outcome was 6/12 or better in 36%, 6/60 or better in 72%, counting fingers in 14%, hand movements in 7%, and no perception of light in 7%. In another epidemic of eight eyes infected by Paecilomyces subsequently required removal. To minimize the risk of epidemic endophthalmitis we use solutions and lenses from different batches when possible.

Epithelial ingrowth is a rare but potentially catastrophic complication. Although there are some large retrospective series, the risk of epithelial ingrowth is hard to estimate. In a review of 207 histological specimens collected over 50 years 123 followed cataract surgery; of these 21 followed ECCE and four phacoemulsification. The nature of the specimens analysed indicates the poor prognosis for the affected eye, enucleation specimens in 41 out of 120, and corneal button 32 out of 120. The median interval between surgery and epithelial ingrowth was 9 months (but the range was 1 week to 38 years), a shorter interval could not be considered an adequate guard against the very remote possibility of simultaneous bilateral epithelial ingrowth.

Non-catastrophic complications

Cystoid macular oedema following immediately sequential ECCE occurred in 12 cases (1.9%), none was bilateral. There were no other reports of cystoid macular oedema after ISCS. The rate of angiographic oedema 60 days after phacoemulsification has been reported as 19%; however, only 1.1% of cases tend to be clinically apparent, and the drop in VA is variable. The outcome of treatment is also variable and can depend on how aggressively it is treated. Cases that have not responded to topical non-steroidal anti-inflammatory drugs, topical steroids, or oral acetzolamide, may yet respond to high dose intravenous methylprednisolone.

In order to reduce the risk of cystoid macular oedema dioclofenac 0.1% eye drops are used to stabilise the blood-aqueous barrier and patients with diabetes mellitus and uveitis, who are more susceptible to blood-aqueous barrier breakdown, are excluded from ISCS. If during the course of the first operation there is vitreous exposure, surgery for the second eye is deferred. The fear of bilateral cystoid macular oedema is probably the most valid reason to delay surgery between eyes, but if it could not be prevented it in the first eye it may not be possible to prevent it in the second eye.

Corneal decompensation and subsequent pseudophakic bullous keratopathy has been estimated to occur following 0.3% of cataract extractions, and is related to endothelial cell loss. Transient epithelial oedema occurred after 0–2.4% of ISCS, but cleared in 2 days. A case of bilateral endothelial failure over 6 months after ISCS resulted in 3/60 vision in one eye and hand movements in the other. Bilateral penetrating keratoplasty was performed, unfortunately the graft failed in one eye, the subsequent vision was 1/60, the successful graft achieved 6/36. No mention of ocular comorbidity was made. Improved phacoemulsification machines and techniques allow cataracts to be removed with less and less energy. In addition, modern viscoelastics dampen the acoustic shock waves generated in proportion to their hyaluronic acid content. Despite this, no significant difference in mean cell loss after phacoemulsification has been found between 1% sodium hyaluronate (Healon), 1.4% sodium hyaluronate (Healon GV), 4% sodium chondroitin sulphate-3% sodium hyaluronate (Viscoat) and 2% hydroxypropyl methylcellulose (Hymece).

Although we exclude patients with endothelial dystrophies or significant guttae, even corneas that appear normal preoperatively may fail postoperatively. The time over which this occurs is variable; thus, a short interval between cataract surgeries may not eliminate the risk. In addition, endothelial failure in one eye may lead the patient to request surgery for the other eye. In the future, the routine use of Healon 5, preoperative specular microscopy, and pachymetry may be used to further reduce the risk of bilateral endothelial failure.

Are the risks acceptable?

Not all simultaneous or immediately sequential surgery attracts such controversy. Immediately sequential blepharoplasty with the risk of bilateral retrolubular haemorrhage is routinely carried out. Bilateral extraocular muscle surgery for the correction of strabismus with the risk of bilateral retinal detachment or endophthalmitis following globe perforation is routinely carried out in children. Immediately sequential laser in situ keratomileusis (LASIK) with the risk of bilateral microkeratome complications and synechial ingrowth is also performed. These immediately sequential bilateral procedures are considered acceptable, not because the risks have been eliminated but rather because the benefits are believed to
outweigh the risks. Many intraoperative and postoperative complications have been reduced by the transition from ECCE to phacoemulsification. Developments continue to be described that aim to improve the outcome of phacoemulsification, and make it an even safer procedure, but there will never be a risk free surgical procedure. With every step of every operation there are choices that require balancing risks and benefits. Currently the benefits of ISCS are more clearly defined than the risks (Table 2).

Estimates of risk vary from “Many things could go wrong during single-eye surgery, and bilateral surgery doubles the chances for error” at one end, to “The risk of bilateral endophthalmitis is no greater than the risk of two sequential patients on an operating list developing endophthalmitis. If a generous endophthalmitis rate of 0.1% is assumed, an ophthalmologist would have to carry out one million cataract operations before two would become infected sequentially. Even the highest volume cataract surgeons would never get near this number in their operating lifetime” at the other. It seems likely that the risk will lie somewhere between these two extremes.

Say the risk of a given complication is one in Y cases or 1/Y. The risk of a complication in either eye is 1/Y + 1/Y = 2/Y. If the eyes are independent the risk of a complication in the second eye is the same as that in the first eye, 1/Y × 1/Y = 1/Y². However, if the patient has an underlying propensity for a complication the risk for the second eye is not independent of the first eye and separating the surgeries is no guarantee that bilateral complications will not occur.

The concept is of conditional probability—that is, the likelihood of the event occurring a second time if it has occurred once already. Maloney estimates if the first eye has a complication then the second will also have the complication one in three times—that is, 1/3Y with LASIK or photorefractive keratectomy.

We have attempted to make similar calculations for the catastrophic complications cited in Table 2. We have searched the literature for cases where both eyes have been affected by expulsive haemorrhage, epithelial ingrowth, and bacterial or fungal endophthalmitis following cataract extraction. These cases have been used to estimate the risk of a patient suffering a catastrophic complication in the second eye if it has already occurred in the first eye (Table 3).

Payne and colleagues reported the 14 eyes with expulsive haemorrhage between 1978 and 1983. In this survey one patient experienced bilateral expulsive haemorrhage associated with cataract extraction and another had their first expulsive haemorrhage at another hospital. The risk to the second eye, after the first has been affected by expulsive haemorrhage, can therefore be estimated as two in 13 or one in 6.5.

Somani and colleagues reported 85 eyes with culture proved bacterial endophthalmitis following ECCE or phacoemulsification between 1989 and 1996, two of these were from the same patient. The risk to the second eye, after the first has been affected by bacterial endophthalmitis, can therefore be estimated as one in 84.

There were no large series of fungal endophthalmitis following cataract surgery. We have pooled the cases of fungal endophthalmitis following cataract extraction from North America and Europe published during the 1990s. We were able to find 33 cases of fungal endophthalmitis by combining cases from series on endophthalmitis and individual reports, and there was only one patient with both eyes affected. The risk to the second eye, after the first has been affected by fungal endophthalmitis, can be very approximately estimated as one in 32. This method would be expected to underestimate the risk to the first eye because not all the cases will be published. However, it will overestimate the risk to the second eye if no cases of bilateral fungal endophthalmitis have been missed.

We were unable to find any reports of bilateral epithelial ingrowth after modern cataract surgery.

Table 3 shows the estimated risks if the complications are considered as independent or not, for the first eye and then the second eye. This clearly demonstrates that the risk of both eyes being affected simultaneously is a small fraction of one eye being affected at a time.

A complication in the first eye may unnecessarily deter the patient from further surgery to the second eye, to the extent that the patient dies blind. It is not simply a question of mathematics and Snellen acuity. A surgeon’s attitude to the risk of bilateral complications after ISCS might depend on when, if ever, they arose. Good results from 9999 patients before the 10 000th suffers a bilateral catastrophic complication might leave a very different impression than if the first patient suffered a catastrophic bilateral complication.

### Conclusion

The risks of ISCS are low if patients suspected of having an underlying predisposition to complications are excluded (Table 1). There are significant, but hard to quantify, benefits to the patient, hospital, and society with ISCS. We are not suggesting that ISCS is for everyone (surgeon and patient alike), but that the stigma attached to ISCS is removed until evidence is found to justify it.

**GUY T SMITH**

**CHRISTOPHER S C LIU**

Sussex Eye Hospital, Eastern Road, Brighton BN2 5BF, UK

Correspondence to: Mr Christopher Liu

CSC.Liu@aol.com

---

**Table 3 The estimated risk of simultaneous bilateral complications in otherwise uncomplicated surgery**

<table>
<thead>
<tr>
<th>Risk estimate</th>
<th>Eyes are independent</th>
<th>Eyes are not independent</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First eye</td>
<td>Second eye</td>
</tr>
<tr>
<td>(A) Expulsive haemorrhage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper limit†</td>
<td>1 in 833</td>
<td>1 in 833</td>
</tr>
<tr>
<td>Lower limit†</td>
<td>1 in 7692</td>
<td>1 in 7692</td>
</tr>
<tr>
<td>(B) Bacterial endophthalmitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper limit†</td>
<td>1 in 555</td>
<td>1 in 555</td>
</tr>
<tr>
<td>Lower limit†</td>
<td>1 in 2141</td>
<td>1 in 2141</td>
</tr>
<tr>
<td>(C) Fungal endophthalmitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1990s‡</td>
<td>1 in 4.62×10⁻⁶</td>
<td>1 in 4.62×10⁻⁶</td>
</tr>
</tbody>
</table>

*Based on ICCE rate.†
‡Derived from 33 cases of published fungal endophthalmitis following an estimated 120 million cataract extractions in the USA in the 1990s.
§Weingold et al.¶


Is it time for a new attitude to “simultaneous” bilateral cataract surgery?


Is it time for a new attitude to "simultaneous" bilateral cataract surgery?

GUY T SMITH and CHRISTOPHER S C LIU

Br J Ophthalmol 2001 85: 1489-1496
doi: 10.1136/bjo.85.12.1489

Updated information and services can be found at:
http://bjo.bmj.com/content/85/12/1489

These include:

References
This article cites 74 articles, 13 of which you can access for free at:
http://bjo.bmj.com/content/85/12/1489#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Lens and zonules (807)
- Choroid (565)
- Eye (globe) (708)
- Ophthalmologic surgical procedures (1223)
- Cornea (524)
- Neurology (1355)
- Ocular surface (618)
- Pupil (51)
- Retina (1608)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/